Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07164313 · ClinicalTrials.gov registry record · Phase 1
A Study of ZW251 in Participants With Advanced Solid Tumors
A Phase 1 study of Hepatocellular Carcinoma, sponsored by Zymeworks BC.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 100
- Enrollment target
- 20
- Study locations
NCT07164313: Recruiting Phase 1 study of Hepatocellular Carcinoma, sponsored by Zymeworks BC.
NCT07164313 is a Phase 1 study of Hepatocellular Carcinoma that is actively recruiting participants, run by Zymeworks BC. The registered enrollment target is 100 participants, below the 257-participant average among 145 other Hepatocellular Carcinoma trials with a reported enrollment target (61% lower). The trial reports 20 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07164313, a Phase 1 study of Hepatocellular Carcinoma, is actively recruiting participants, sponsored by Zymeworks BC.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 100 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to find out if ZW251, an antibody-drug conjugate targeting glypican-3 (GPC3), is safe and can treat participants with advanced cancers, including hepatocellular carcinoma (HCC).
Primary Outcome
Number of participants who experienced a DLT. DLTs include specifically defined adverse events (AEs) considered to be related to ZW251
Conditions Studied
Interventions
- DRUG ZW251
Study Locations (20)
Other
- START - Dublin Mater Misericordiae University Hospital (MMUH) - Dublin
- National Cancer Center East - Kashiwa
- Kyoto University Hospital - Kyoto
- Kansai Medical University Hospital - Osaka
- National Cancer Center Hospital - Tokyo
- START Lisboa a - Unidade de Ensaios ClÃnicos - Hospital de Santa Maria - Lisbon
- Hospital Universitario Vall d'Hebron - Barcelona
- START Barcelona - Barcelona
- START - Rioja Hospital Universitario San Pedro - Logroño
- START Madrid Hospital Universitario Fundacion Jimenez Diaz - Madrid
- START Madrid Hospital Universitario HM Sanchinarro - CIOCC - Madrid
- NEXT Oncology Madrid - Madrid
- National Taiwan University Hospital - Taipei
- Taipei Veterans General Hospital - Taipei
Texas
- MD Anderson Cancer Center - Houston
- START San Antonio - San Antonio
California
- UCSF Comprehensive Cancer Center - San Francisco
Kentucky
- Norton Cancer Institute - Louisville
Michigan
- START Midwest - Grand Rapids
New Jersey
- Hackensack University Medical Center - Hackensack
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2025-10-21 |
| Est. Completion | 2028-05 |
| Phase | Phase 1 |
What NCT07164313 shows while recruiting
NCT07164313 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 257-participant average among 145 other Hepatocellular Carcinoma trials with a reported enrollment target (61% lower).
The record links to 1 condition, with Hepatocellular Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which ZW251 is the first listed.
NCT07164313 names 20 study sites across 6 states, led by Other, Texas, California.
Frequently Asked Questions
What is clinical trial NCT07164313 about?
NCT07164313 is a clinical study titled "A Study of ZW251 in Participants With Advanced Solid Tumors". The purpose of this study is to find out if ZW251, an antibody-drug conjugate targeting glypican-3 (GPC3), is safe and can treat participants with advanced cancers, including hepatocellular carcinoma (HCC).
What is the current status of trial NCT07164313?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 100 participants. The study started on 2025-10-21. Estimated completion is 2028-05.
What conditions does trial NCT07164313 study?
This clinical trial studies the following conditions: Hepatocellular Carcinoma.
What interventions are being tested in trial NCT07164313?
The interventions under investigation include: ZW251 (DRUG).
Who is sponsoring clinical trial NCT07164313?
This trial is sponsored by Zymeworks BC, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07164313 being conducted?
This trial has 20 study locations across California, Kentucky, Michigan, New Jersey, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hepatocellular Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07164313's enrollment target sits among peer trials
100 59th of 145 higher than 82 of 145 other Hepatocellular Carcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hepatocellular Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
RECRUITING · Phase 1
-
Immunotherapy For Adults With GPC3-Positive Solid Tumors Using IL-15 and IL-21 Armored GPC3-CAR T Cells
RECRUITING · Phase 1
-
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
RECRUITING · Phase 1
-
Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
RECRUITING · Phase 1
-
Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients
RECRUITING · Phase 1
-
Cryoablation and Arterial Infusion of SD-101 in Combination with Durvalumab and Tremelimumab
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI